

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
10 October 2002 (10.10.2002)

PCT

(10) International Publication Number  
**WO 02/078665 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 7/48**

(21) International Application Number: **PCT/US01/10407**

(22) International Filing Date: **30 March 2001 (30.03.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(71) Applicant (*for all designated States except US*): **COLOR ACCESS, INC.** [US/US]; 7 Corporate Center Drive, Melville, NY 11747 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **PAINTER, Rachel, J.** [US/US]; Apartment 4, 876 President Street, Brooklyn, NY 11215 (US). **COHEN, Isaac, D.** [US/US]; 1939 East 9th Street, Brooklyn, NY 11223 (US). **IONITA-MAN-ZATU, Mirela, C.** [RO/US]; 256 Haypath Road, Bethpage, NY 11804 (US).

(74) Agent: **LOWNEY, Karen, A.**; Color Access, Inc., 125 Pinelawn Road, Melville, NY 11747 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **ENCAPSULATED DYES IN COSMETIC COMPOSITIONS**

(57) Abstract: The invention relates to a topical composition for application to skin comprising a cosmetically or pharmaceutically acceptable encapsulated liquid UV-absorbing naphthopyran or naphthoxazine dye, or a combination thereof, in combination with a cosmetically or pharmaceutically acceptable carrier.

## ENCAPSULATED DYES IN COSMETIC COMPOSITIONS

Field of the Invention

5 The invention relates to cosmetic compositions. More specifically, the invention relates to cosmetic compositions containing encapsulated UV-absorbing dyes.

Background of the Invention

10 The stability of cosmetic formulations and the individual components contained therein is a constant source of concern. Cosmetic components can be subject to many different types of environmental stresses, the major elements being heat, oxidation and light. Obviously, the solution to these problems can be approached by specialized packaging or storage conditions, such as airtight containers, UV-resistant or darkened glass containers and the like. However, such approaches are frequently costly and/or impractical for many types of products. Therefore, a preferred approach is to incorporate protective components into the composition. In some cases, the components perform a dual function, potentially protecting both the composition and the skin to which it is applied; this is true of certain antioxidants, for example. Because such a solution is not only ordinarily more cost efficient, but can add value to the product, there is a constant search for ingredients that will assist in maintaining the integrity of a composition throughout long-term exposure to one or more of these elements, as well as providing benefit to the performance of the product. The present invention now provides compositions incorporating such ingredients.

Summary of the Invention

25 The invention relates to topical compositions comprising cosmetically or pharmaceutically acceptable encapsulated UV-absorbing dyes selected from the group consisting of naphthopyrans and naphthoxazines, or combinations thereof. The dyes are preferably encapsulated as a liquid phase, and preferably in a two-layered capsule, the outer layer of the capsule comprising an acrylates copolymer. The encapsulated dyes also exhibit antioxidant activity, thereby providing a dual function when used in a topical composition.

30 Brief Description of the Figures

, Figure 1 illustrates the antioxidant activity of PCME Blue Dye(Color Change Corporation) as shown in both LPO-UVB induced liposome assay(A) and LPO-ascorbic acid induced assay(B).

Figure 2 illustrates the antioxidant activity of PCME Yellow Dye(Color Change Corporation)as shown in an LPO-ascorbic acid induced assay.

#### Detailed Description of the Invention

5 The compositions of the invention contain one or more encapsulated UV-absorbing dyes. The dyes of choice for this invention are naphthopyran and naphthoxazine dyes. Each of these categories has two main subclasses; for naphthopyrans, these are 2H-naphtho[1,2-b]pyrans and 3H-naphtho[2,1-b]pyrans, and for naphthoxazines, these are naphth[2,1-b][1,4]oxazines and naphth[1,2-b][1,4]oxazines. Dyes of this type are available commercially, 10 for example under the tradename Photosol®, from PPG. Particularly preferred dyes are spiroxazines, such as 1,3-dihydro-1,3,3,5,6-pentamethyl-spiro(2H-indole-2,3-(3H)naphtho(2,1b)-(1,4) oxazine, and naphthopyrans, such as 3,3 diphenyl-3H-naphtho(2,1-b)pyran.. Such dyes have been used industrially as components of printing inks, but are not frequently used in topical compositions for application to the skin. Although certain dyes of 15 this type have been identified as having UV-absorbing properties, in the present case, the dyes are encapsulated. The dyes themselves may be susceptible to exhaustion by exposure to light, which over time may alter their ability to respond to UV radiation and also weaken their stability. Thus, the encapsulation provides a measure of photostability to the dye itself, and yet adequately permits the dye to absorb UV substantially in accordance with its usual 20 function. Preferably, the dyes are encapsulated in liquid form within a microcapsule. Encapsulated dyes are available commercially from a number of sources, for example, the Reversacol dyes from Keystone/James Robinson. Preferred for the present purposes, however, are liquid dyes encapsulated in a dual chambered capsule, the outer wall of the capsule comprising an acrylates copolymer as a primary component. This type of encapsulated 25 dye can be purchased commercially under the product name PCME, from Color Change Corporation, Addison, Illinois. These encapsulated dyes are particularly useful because, unlike certain other types of microcapsules, there is substantially no formaldehyde generated by them. Although the amount of encapsulated dyes used is not particularly critical, especially as to the upper limit, they will normally be present in the formulation in an amount of from 30 about 0.5 to about 20% by weight, more preferably from about 1 to about 10% by weight, of the total composition.

The encapsulated dyes can be added to any type of cosmetic formulation in which UV-absorption properties are desirable. In one embodiment, the dyes are added to a color cosmetic formulation. Typical color cosmetic formulations include foundations, powders,

eyeshadows, blushes, concealers, lipsticks and glosses, eyeliners, bronzers, and the like, i.e., anything intended to confer color to the skin. In such compositions, the encapsulated dyes are combined with other pigments or dyes, for example, inorganic pigments including iron oxides (yellow, red, brown or black), ferric ammonium ferrocyanide (blue), manganese violet, ultramarine blue, chrome oxide (green), talc, lecithin modified talc, zeolite, kaolin, lecithin modified kaolin, titanium dioxide (white), zinc oxide and mixtures thereof. Also useful are transparent metal oxide-coated silica beads. Metal oxides, particularly iron and titanium oxides, including doped (photochromic) titanium dioxides, are preferred inorganic pigments in the composition of the invention, particularly for foundations.

Organic pigments can also be used in the compositions of the invention; these include natural colorants and synthetic monomeric and polymeric colorants. Exemplary are phthalocyanine blue and green pigment, diarylide yellow and orange pigments, and azo-type red and yellow pigments such as toluidine red, litho red, naphthol red and brown pigments. Also useful are lakes, which are pigments formed by the precipitation and absorption of organic dyes on an insoluble base, such as alumina, barium, or calcium hydrates. Particularly preferred lakes are primary FD&C or D&C Lakes and blends thereof. Stains, such as bromo dyes and fluorescein dyes can also be employed. The amount and type of pigment used will vary depending upon the nature of the final product and the desired intensity of color; generally, however, the amount of pigment will be about 1 to about 20% by weight of the total composition.

The encapsulated dyes can also be used in a non-color cosmetic, for example a skin care product substantially without any added color. Examples of such products include, but are not limited to, moisturizers (which may be tinted or non-tinted), lip balms, sunscreen formulations, antiaging formulations, skin whitening formulations, exfoliating formulations, and the like. In this regard, the encapsulated dyes can also be formulated with various skin-related active components, such as analgesics, anesthetics, anti-acne agents, antibacterials, antiyeast agents, antifungal agents, antioxidants, antiviral agents, antidandruff agents, antidermatitis agents, antipruritic agents, antiemetics, antimotion sickness agents, anti-irritant agents, anti-inflammatory agents, antihyperkeratolytic agents, anti-dry skin agents, antiperspirants, antipsoriatic agents, antiseborrheic agents, hair conditioners and hair treatment agents, antiaging agents, antiwrinkle agents, sunscreen agents, antihistamine agents, skin lightening agents, depigmenting agents, wound-healing agents, vitamins, corticosteroids, self-tanning agents, or hormones.

The formulations, either color or non-color, can also incorporate one or more pearlescent powders or pigments, such as titanium dioxide coated talc, titanium dioxide coated mica, titanium dioxide coated bismuth oxychloride, and bismuth oxychloride. Additional nonpearlescent powders can also be used, such as kaolin, mica, talc, calcium carbonate, silica, sericite, biotite, boron nitride, polyethylene, nylon, polystyrene, polymethyl methacrylate, cellulose, methyl methacrylate cross polymer, and calcium aluminum borosilicate.

The encapsulated dyes can be incorporated into virtually any type of vehicle. The products of the invention can take any form which is typical of cosmetic products, for example, hot pour formulations, water-in-oil emulsions, oil-in-water emulsions, gels, sticks, sprays, anhydrous formulations, and pressed or loose powders. There is no limitation on the type of vehicle that can be employed. In particular, the preferred identity of the vehicle will be largely controlled by the type of product into which the components are to be incorporated. Principles of topical formulation are well known in the art, and can be found, for example in Remington's Pharmaceutical Sciences, 18<sup>th</sup> Edition(1990), incorporated herein by reference.

The formulation also can comprise other components which may be chosen depending on the carrier and/or the intended use of the formulation. Additional components include, but are not limited to, water soluble colorants (such as FD&C Blue #1); oil soluble colorants (such as D&C Green #6); water soluble sunscreens (such as Eusolex 232); oil soluble sunscreens (such as octyl methoxycinnamate); particulate sunscreens (such as zinc oxide); antioxidants (such as BHT); chelating agents (such as disodium EDTA); emulsion stabilizers (such as carbomer); preservatives (such as methyl paraben); fragrances (such as pinene); flavoring agents (such as sorbitol); humectants (such as glycerine); waterproofing agents (such as PVP/Eicosene copolymer); water soluble film-formers (such as hydroxypropyl methylcellulose); oil-soluble film formers (such as hydrogenated C-9 Resin); moisturizing agents, such as cholesterol; cationic polymers (such as Polyquaternium 10); anionic polymers (such as xanthan gum); pigment wetting agents, such as Arlacel™ P100, or Emerest™ 2452; vitamins (such as tocopherol); and the like. Typical components of topical formulations can also be found in the International Cosmetic Ingredient Dictionary and Handbook, 8<sup>th</sup> edition(2000), incorporated by reference herein in their entirety.

In addition to the UV-absorbing properties, a number of the encapsulated dyes of the invention also exhibit a surprising anti-inflammatory/antioxidant property. Thus, when added to a topical formulation, the dyes also provide an additional functionality, i.e., to treat or prevent inflammation, as well as to reduce the presence of oxygen both in the formulation and on the skin.

The invention will be further illustrated by the following non-limiting examples

## EXAMPLES

### 10 Example I:

A water in oil emulsion of the present invention is prepared as follows:

	Material	Weight %
	Phase I	
15	Phenyl trimethicone	12.20
	Bentone gel	8.00
	Cyclomethicone	4.00
	Phase II	
20	Cyclomethicone	12.00
	Cyclomethicone/dimethicone	11.50
	Cetyl dimethicone copolyol/polyglyceryl-4	
	Isostearate/hexyl laurate	0.50
	Dimethicone copolyol/cyclomethicone	3.00
25	Phase 3	
	Silica/TiO <sub>2</sub> /dimethicone	7.00
	Mica/silica/dimethicone	2.86
	Propyl paraben	0.10
30	Phase 4	
	Purified water	QS
	Butylene glycol	6.00
	Sodium chloride	1.00
	Phenoxyethanol	0.70

Benzyl alcohol

0.0001

Laureth-7

0.15

Phase 5

5 PCME yellow

3.00

PCME red

2.00

Titanium dioxide/iron oxides

0.14

Phases 1 and 2 are combined under propeller mixing. Phase 3 is then added and mixed well.

10 Phase 4 is then added slowly to the mixture while it is under propeller. Sequence 5 is then added and mixed well.

### Example II

This example illustrates the antioxidant activity of the encapsulated dyes of the invention.

15

PCME encapsulated dyes Red, Blue and Yellow are evaluated for their antioxidant activity in two different assays, an LPO-UVB induced liposome assay, and an LPO-ascorbic acid induced assay. Although Red, only tested up to a level of 0.5%, exhibits no activity in either assay, both Blue and Yellow, tested at levels up to 1.5%, do show antioxidant activity in one  
20 or both assays. More specifically, Blue shows moderate activity in the LPO-UVB assay, with an IC value of 0.94%, whereas Yellow shows none. However, in the LPO-ascorbic acid assay, both Blue and Yellow dyes exhibit moderate antioxidant activity, with IC values of 0.69% and 0.98% respectively. These results are shown in Figures 1 and 2.

What we claim is:

1. A topical composition for application to skin comprising a cosmetically or pharmaceutically acceptable encapsulated liquid UV-absorbing naphthopyran or naphthoxazine dye, or a combination thereof, in combination with a cosmetically or pharmaceutically acceptable carrier.
2. The composition of claim 1 in which the dye is encapsulated in a dual walled capsule, the outer layer of which comprises an acrylates copolymer.
3. The composition of claim 1 which additionally comprises a cosmetically acceptable pigment.
4. The composition of claim 2 which additionally comprises a cosmetically acceptable pigment.
5. The composition of claim 3 which comprises an inorganic pigment.
6. The composition of claim 4 which comprises an inorganic pigment.
7. The composition of claim 3 which comprises a pearlescent pigment.
8. The composition of claim 4 which comprises a pearlescent pigment.
9. The composition of claim 1 which also comprises a skin care active.
10. The composition of claim 2 which also comprises a skin care active.
11. The composition of claim 9 which comprises at least one sunscreen.
12. The composition of claim 10 which comprises at least one sunscreen.
13. The composition of claim 1 in which the encapsulated dyes are present in an amount of from about 0.5 to about 20 % by weight of the total composition.



14. The composition of claim 2 in which the encapsulated dyes are present in an amount of from about 0.5 to about 20 % by weight of the total composition.

- 5 15. A topical composition for application to skin comprising a cosmetically or pharmaceutically acceptable encapsulated liquid UV-absorbing naphthopyran or naphthoxazine dye, or a combination thereof, the dye being encapsulated in a dual walled capsule, the outer layer of which comprises an acrylates copolymer, in combination with a cosmetically or pharmaceutically acceptable carrier.




Fig. 1A




Fig. 1B




Fig. 2

## INTERNATIONAL SEARCH REPORT

Intern      Application No  
PCT/US 01/10407A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7      A61K7/48

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7      A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 619 314 A (ELI LILLY AND COMPANY) 12 October 1994 (1994-10-12) abstract page 7, line 22 examples 2-19,21	1, 13, 14
Y	---	2-12, 15
Y	EP 0 480 162 A (MATSUI SHIKISO CHEMICAL CO.) 15 April 1992 (1992-04-15) page 6, line 58 -page 7, line 22 example 6	2-12, 15
Y	EP 0 970 689 A (L'OREAL) 12 January 2000 (2000-01-12) paragraph '0023!; example 1 claims 1,2,5-11	2-12, 15
	--- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

4 February 2002

Date of mailing of the international search report

11/02/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Alvarez Alvarez, C

## INTERNATIONAL SEARCH REPORT

Intern I Application No  
PCT/US 01/10407

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 160 844 A (ORR ET AL.) 10 July 1979 (1979-07-10) column 2, line 3 - line 27 examples 1-7 claims 1-7 -----	1



## INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern: Application No

PCT/US 01/10407

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 619314	A	12-10-1994	CA	2120861 A1	10-10-1994
			EP	0619314 A1	12-10-1994
			JP	6321929 A	22-11-1994
			US	5514706 A	07-05-1996
			US	5624953 A	29-04-1997
EP 480162	A	15-04-1992	AU	642529 B2	21-10-1993
			AU	8450091 A	16-04-1992
			BR	9104373 A	09-06-1992
			CA	2051000 A1	10-04-1992
			CN	1061252 A	20-05-1992
			CS	9103074 A3	15-04-1992
			DE	480162 T1	24-09-1992
			EP	0480162 A1	15-04-1992
			ES	2044826 T1	16-01-1994
			FI	914630 A	10-04-1992
			GR	92300086 T1	30-12-1992
			IE	921113 A1	18-11-1992
			JP	5033276 A	09-02-1993
			JP	7049631 B	31-05-1995
			MX	9101406 A1	31-05-1994
			NO	913817 A	10-04-1992
			NZ	239231 A	26-07-1994
			PL	291958 A1	27-07-1992
			PT	99173 A	30-09-1992
			TR	26137 A	15-02-1995
			US	5221288 A	22-06-1993
EP 970689	A	12-01-2000	FR	2780275 A1	31-12-1999
			BR	9903099 A	06-02-2001
			EP	0970689 A2	12-01-2000
			JP	2000038329 A	08-02-2000
			US	6080415 A	27-06-2000
US 4160844	A	10-07-1979	GB	1560489 A	06-02-1980
			AU	508191 B2	13-03-1980
			AU	2519677 A	23-11-1978
			BE	854691 A1	16-11-1977
			CA	1085298 A1	09-09-1980
			DE	2722916 A1	01-12-1977
			DK	223377 A	22-11-1977
			FI	771582 A	22-11-1977
			FR	2361387 A1	10-03-1978
			IE	45200 B1	14-07-1982
			IL	52103 A	13-09-1981
			JP	53015428 A	13-02-1978
			LU	77365 A1	13-12-1977
			NL	7705561 A	23-11-1977
			NO	771766 A	22-11-1977
			NZ	184140 A	20-06-1978
			SE	7705851 A	22-11-1977
			US	4269853 A	26-05-1981
			ZA	7702990 A	26-04-1978

